Search

for
Search:

Did you mean TYK2 Inhibitor?

GlossaryTYK2 Inhibitor

blocks enzyme activity to reduce inflammation in autoimmune diseases

A TYK2 inhibitor is a type of medication that blocks the activity of the TYK2 enzyme, which is involved in the immune system's signaling pathways. By inhibiting this enzyme, these drugs can help reduce inflammation and are being researched for treating autoimmune diseases like psoriasis and alopecia areata.

Related Terms

Research

5 / 243 results

research JAK 1-3 inhibitors and TYK-2 inhibitors in dermatology: Practical pearls for the primary care physician

6 citations , October 2024 in “Journal of Family Medicine and Primary Care”

Primary care doctors need to monitor JAK and TYK-2 inhibitors carefully for skin conditions.

research 544 Alopecia areata lesions show significant changes in immune and keratin biomarkers that correlate with clinical improvement with oral Janus kinase inhibitors PF-06651600 (JAK3) and PF-06700841 (TYK2/JAK1)

5 citations , April 2019 in “Journal of Investigative Dermatology”

Oral JAK inhibitors improved alopecia areata by modulating immune responses and boosting hair growth.

research 265 Modulation of disease-central cytokine pathways with TAK-279, a highly selective oral tyrosine kinase 2 (TYK2) inhibitor, defines clinical response in patients with psoriasis

1 citations , July 2024 in “Journal of Investigative Dermatology”

TAK-279 effectively reduces psoriasis symptoms and is safe.

research Innovative Therapeutic Strategies in TYK2-Targeted Treatments: From Cancer to Autoimmune Disorders

1 citations , January 2024 in “ACS Medicinal Chemistry Letters”

TYK2 inhibitors show promise for treating cancer and autoimmune disorders.

TYK2 Inhibition with Deucravacitinib Improves Clinical Outcomes and Resolves Interferon-Driven Inflammation in Lichen Planopilaris

research TYK2 Inhibition with Deucravacitinib Improves Clinical Outcomes and Resolves Interferon-Driven Inflammation in Lichen Planopilaris

March 2026

Deucravacitinib improves symptoms and reduces inflammation in Lichen Planopilaris.

View more "tyk-2 inhibitor" in research →

Community Join

1 / 1000+ results

community Kintor Phase 2 Results released KX-826 (pyrilutamide)

in Research/Science 444 upvotes 3 years ago

Kintor Pharmaceutical's Phase 2 results with the drug Pyrilutamide, a potential alternative to 5-ARI drugs like Finasteride and Dutasteride but without the side effects. It could be used in combination with other topical treatments such as Minoxidil. The safety of the drug has been demonstrated in 6 months of use, however there are still questions about long term efficacy and systemic absorption.

View more "tyk-2 inhibitor" in community →